Meeting
2020 ASCO Virtual Scientific Program
BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC.
Authors
Yasir Elamin
The University of Texas MD Anderson Cancer Center, Houston, TX
Yasir Elamin , Saumil Gandhi , Mara Antonoff , Frank Mott , Don Lynn Gibbons , Xiuning Le , Marcelo Vailati Negrao , Boris Sepesi , Jose A. Karam , Tina Cascone , Linghua Wang , George Blumenschein Jr., Bonnie S. Glisson , Anne S. Tsao , John Heymach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03707938
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9624)
DOI
10.1200/JCO.2020.38.15_suppl.9624
Abstract #
9624
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge
Poster
2024 ASCO Annual Meeting
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
First Author: Kyle Concannon
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2023 ASCO Annual Meeting
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
First Author: D. Ross Camidge